Merck, CLL1219AM-1VL, Safe Harbor Landing Pad Cell Line A375 Cancer Cells

General description
The STR profile of this cell line matches that of its parental cell line ATCC® Catalog No. CRL-1619. A375 are a human malignant melanoma cell line isolated from a 54 year old female. The cells possess a hypotriploid karyotype.
Application
This product is a human A375 melanoma cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr® Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.
Biochem/physiol Actions
These cells are a human malignant melanoma cell line isolated from a 54-year old female. The cells possess a hypotriploid karyotype.
Features and Benefits
These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These A375 cells are adherent with a doubling time of approximately 22 hours.
Preparation Note
DMEM (Catalog Number D6429) with 10% FBS (Catalog Number F2442)
Analysis Note
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, short terminal repeat (STR) analysis for cell line identification.
Legal Information
ATCC is a registered trademark of American Type Culture Collection
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany